Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Regimen Change

Displaying 11 papers

From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations

Publication: Malhotra S, Ursu I, Ghoneim R, et. al. From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:32-8. doi: 10.5588/ijtld.15.0482.

12/2015

Tags: Childhood TB, Policy, Regimen Change, TB Drug Market, TB Market

Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations

Publication: Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:61-8. doi: 10.5588/ijtld.15.0435.

12/2015

Tags: Advocacy, Childhood TB, Editorials, MDR-TB, Regimen Change

The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective

Publication: Scott C, Gardiner E, de Lucia A. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:17-22. doi: 10.5588/ijtld.15.0478.

12/2015

Tags: Advocacy, Childhood TB, Policy, Regimen Change, TB Burden, TB Drug Market, TB Market

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.

3/2012

Tags: Advocacy, Childhood TB, Clinical Development, Drug Discovery, Drug-Sensitivity Testing, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Policy, Preclinical Models, Pretomanid/PA-824, Regimen Change, TB Market, TB-HIV, Trial Design

Moxifloxacin for tuberculosis

Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.

3/2012

Tags: Advocacy, Clinical Development, Drug-Sensitivity Testing, Editorials, MDR-TB, Moxifloxacin, Policy, Regimen Change

Implications of the current tuberculosis treatment landscape for future regimen change

Publication: Wells WA, Konduri N, Chen C, et.al. Implications of the current tuberculosis treatment landscape for future regimen change. Int J Tuberc Lung Dis. 2011 Jun;15(6):746-53. doi: 10.5588/ijtld.10.0094.

6/2011

Tags: Drug-Sensitivity Testing, HRZE, MDR-TB, Policy, Regimen Change, TB Market

Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making

Publication: Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

3/2011

Tags: Advocacy, Policy, Regimen Change, TB Market

Tuberculosis regimen change in high-burden countries

Publication: Wells WA, Konduri N, Chen C, et.al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010 Dec;14(12):1538-47.

12/2010

Tags: Advocacy, Editorials, Policy, Regimen Change, TB Market

Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships

Publication: Brooks AD, Wells WA, McLean TD, et. al. Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships. 2010. Innovation Strategy Today 2010 Jan. 3:1-5.

1/2010

Tags: Advocacy, Policy, Regimen Change, TB Market

Estimating the market for tuberculosis drugs in industrialized and developing nations

Publication: Schwalbe NR, Wells WA, Geaneotes AP, et. al. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis. 2008 Oct;12(10):1173-81. http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000010/a

10/2008

Tags: Regimen Change, TB Burden, TB Drug Market, TB Market

Timing of Default From Tuberculosis Treatment: A Systematic Review

Publication: Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health. 2008 May;13(5):703-12. doi: 10.1111/j.1365-3156.2008.02042.x.

5/2008

Tags: Advocacy, Policy, Regimen Change, TB Market